RxDoctor Payments Data

Sherry Wheelock

Adult Health · Canajoharie, NYNPI 1821437120

Payments from drug & device makers

$1,728in general payments, 2019–2025

Across 39 payments — averaging $44.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$909
  • Avanir Pharmaceuticals, Inc.$263
  • AstraZeneca$215
  • SK Life Science, Inc.$125
  • Acadia Pharmaceuticals Inc$109
  • Insulet Corporation$43
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$1,728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,728 in reported general payments places this provider in the 75th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$275,896
Medicare patients
319
Services billed
3,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban494$151,255
TrulicityDulaglutide165$149,413
IngrezzaValbenazine Tosylate38$137,667
FingolimodFingolimod Hcl13$110,288
RexultiBrexpiprazole94$78,539
Lagevrio (Eua)Molnupiravir70$56,651
Invega SustennaPaliperidone Palmitate14$51,676
OzempicSemaglutide40$41,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$37,494
NuedextaDextromethorphan Hbr/Quinidine40$30,177
XareltoRivaroxaban97$28,737
ZenpepLipase/Protease/Amylase11$19,774
Breo ElliptaFluticasone/Vilanterol45$19,425
ArexvyRsvpref3 Antigen/As01e/Pf61$19,294
XifaxanRifaximin11$17,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$27$149,413165 claims
Neurocrine Biosciences, Inc.Ingrezza$909$137,66738 claims
Avanir Pharmaceuticals, Inc.Nuedexta$263$30,17740 claims
AstraZenecaFarxiga$215$6,71921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,828 adult health providers in New York.

Other adult health in Canajoharie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →